{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:11:03Z","timestamp":1789056663947,"version":"build-2803163510"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["72274045"],"award-info":[{"award-number":["72274045"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Patient"],"DOI":"10.1007\/s40271-026-00838-x","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:57:15Z","timestamp":1789055835000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment Preferences for Acute Myeloid Leukemia in Harbin, China: A Discrete Choice Experiment Among Patients, Caregivers, and Hematologists"],"prefix":"10.1007","author":[{"given":"Lemin","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haofei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyao","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6107-5305","authenticated-orcid":false,"given":"Weidong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"838_CR1","doi-asserted-by":"publisher","first-page":"e303","DOI":"10.1016\/j.clml.2018.05.003","volume":"18","author":"JA Bell","year":"2018","unstructured":"Bell JA, Galaznik A, Huelin R, Stokes M, Guo Y, Fram RJ, et al. Effectiveness and safety of therapeutic regimens for elderly patients with acute myeloid leukemia: a systematic literature review. Clin Lymphoma Myeloma Leuk. 2018;18:e303\u201314. https:\/\/doi.org\/10.1016\/j.clml.2018.05.003.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"838_CR2","doi-asserted-by":"publisher","DOI":"10.1200\/GO.23.00229","volume":"9","author":"CT Jani","year":"2023","unstructured":"Jani CT, Ahmed A, Singh H, Mouchati C, Al Omari O, Bhatt PS, et al. Burden of AML, 1990\u20132019: estimates from the global burden of disease study. JCO Glob Oncol. 2023;9:e2300229. https:\/\/doi.org\/10.1200\/GO.23.00229.","journal-title":"JCO Glob Oncol."},{"key":"838_CR3","doi-asserted-by":"publisher","first-page":"1629111","DOI":"10.3389\/fmed.2025.1629111","volume":"12","author":"X Lu","year":"2025","unstructured":"Lu X, Peng X, Zhang Y, Zhu H, Zheng Y, Sun Y, et al. Global and Chinese trends in acute myeloid leukemia burden (1990\u20132021): a comprehensive analysis based on the GBD study. Front Med (Lausanne). 2025;12:1629111. https:\/\/doi.org\/10.3389\/fmed.2025.1629111.","journal-title":"Front Med (Lausanne)."},{"key":"838_CR4","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/ajh.27625","volume":"100","author":"S Shimony","year":"2025","unstructured":"Shimony S, Stahl M, Stone RM. Acute myeloid leukemia: 2025 update on diagnosis, risk\u2010stratification, and management. Am J Hematol. 2025;100:860\u201391. https:\/\/doi.org\/10.1002\/ajh.27625.","journal-title":"Am J Hematol"},{"key":"838_CR5","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1080\/03007995.2019.1631149","volume":"35","author":"NL Crossnohere","year":"2019","unstructured":"Crossnohere NL, Richardson DR, Reinhart C, O\u2019Donoghue B, Love SM, Smith BD, et al. Side effects from acute myeloid leukemia treatment: results from a national survey. Curr Med Res Opin. 2019;35:1965\u201370. https:\/\/doi.org\/10.1080\/03007995.2019.1631149.","journal-title":"Curr Med Res Opin"},{"key":"838_CR6","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s11899-022-00680-6","volume":"17","author":"G Granroth","year":"2022","unstructured":"Granroth G, Khera N, Arana Yi C. Progress and challenges in survivorship after acute myeloid leukemia in adults. Curr Hematol Malig Rep. 2022;17:243\u201353. https:\/\/doi.org\/10.1007\/s11899-022-00680-6.","journal-title":"Curr Hematol Malig Rep"},{"key":"838_CR7","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424\u201347. https:\/\/doi.org\/10.1182\/blood-2016-08-733196.","journal-title":"Blood"},{"key":"838_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01143-2","volume":"14","author":"H Kantarjian","year":"2024","unstructured":"Kantarjian H, Borthakur G, Daver N, DiNardo CD, Issa G, Jabbour E, et al. Current status and research directions in acute myeloid leukemia. Blood Cancer J. 2024;14:163. https:\/\/doi.org\/10.1038\/s41408-024-01143-2.","journal-title":"Blood Cancer J"},{"key":"838_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01424-6","volume":"16","author":"RS Bhansali","year":"2023","unstructured":"Bhansali RS, Pratz KW, Lai C. Recent advances in targeted therapies in acute myeloid leukemia. J Hematol Oncol. 2023;16:29. https:\/\/doi.org\/10.1186\/s13045-023-01424-6.","journal-title":"J Hematol Oncol"},{"key":"838_CR10","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1158\/1055-9965.EPI-19-1277","volume":"29","author":"DR Richardson","year":"2020","unstructured":"Richardson DR, Crossnohere NL, Seo J, Estey E, Smith BD, Bridges JFP. Age at diagnosis and patient preferences for treatment outcomes in AML: a discrete choice experiment to explore meaningful benefits. Cancer Epidemiol Biomarkers Prev. 2020;29:942\u20138. https:\/\/doi.org\/10.1158\/1055-9965.EPI-19-1277.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"838_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00671-z","volume":"12","author":"E Ouchveridze","year":"2022","unstructured":"Ouchveridze E, Banerjee R, Desai A, Aziz M, Lee-Smith W, Mian H, et al. Financial toxicity in hematological malignancies: a systematic review. Blood Cancer J. 2022;12:74. https:\/\/doi.org\/10.1038\/s41408-022-00671-z.","journal-title":"Blood Cancer J"},{"key":"838_CR12","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.pharp.2025.03.002","volume":"1","author":"N Li","year":"2025","unstructured":"Li N, Fu W, Lei J, Zhang J, You C, Lin J, et al. Construction of a value assessment framework for antineoplastic agents based on multi-criteria decision analysis in the context of diagnosis related group. Pharmacoecon Policy. 2025;1:42\u201350. https:\/\/doi.org\/10.1016\/j.pharp.2025.03.002.","journal-title":"Pharmacoecon Policy"},{"key":"838_CR13","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1007\/s00432-021-03579-6","volume":"147","author":"L Josfeld","year":"2021","unstructured":"Josfeld L, Keinki C, Pammer C, Zomorodbakhsch B, H\u00fcbner J. Cancer patients\u2019 perspective on shared decision-making and decision aids in oncology. J Cancer Res Clin Oncol. 2021;147:1725\u201332. https:\/\/doi.org\/10.1007\/s00432-021-03579-6.","journal-title":"J Cancer Res Clin Oncol"},{"key":"838_CR14","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s40487-022-00200-9","volume":"10","author":"TW LeBlanc","year":"2022","unstructured":"LeBlanc TW, Russell NH, Hernandez-Aldama L, Panter C, Bell TJ, Welch V, et al. Patient, family member and physician perspectives and experiences with AML treatment decision-making. Oncol Ther. 2022;10:421\u201340. https:\/\/doi.org\/10.1007\/s40487-022-00200-9.","journal-title":"Oncol Ther"},{"key":"838_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11598-4","volume":"23","author":"M Zhang","year":"2023","unstructured":"Zhang M, He X, Wu J, Xie F. Differences between physician and patient preferences for cancer treatments: a systematic review. BMC Cancer. 2023;23:1126. https:\/\/doi.org\/10.1186\/s12885-023-11598-4.","journal-title":"BMC Cancer"},{"key":"838_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12910-026-01422-6","volume":"27","author":"J-R Li","year":"2026","unstructured":"Li J-R, Walker S, Nie J-B. \u201cBecause this is my body\u201d: patients\u2019, families\u2019 and health professionals\u2019 perspectives on family-oriented informed consent in China. BMC Med Ethics. 2026;27:75. https:\/\/doi.org\/10.1186\/s12910-026-01422-6.","journal-title":"BMC Med Ethics"},{"key":"838_CR17","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.2147\/PPA.S442530","volume":"18","author":"DJ Mott","year":"2024","unstructured":"Mott DJ, Hitch J, Nier S, Pemberton-Whiteley Z, Skedgel C. Patient Preferences for Treatment in Relapsed\/Refractory Acute Leukemia in the United Kingdom: A Discrete Choice Experiment. Patient Prefer Adherence. 2024;18:1243\u201355. https:\/\/doi.org\/10.2147\/PPA.S442530.","journal-title":"Patient Prefer Adherence"},{"key":"838_CR18","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1002\/pon.5652","volume":"30","author":"DR Richardson","year":"2021","unstructured":"Richardson DR, Oakes AH, Crossnohere NL, Rathsmill G, Reinhart C, O\u2019Donoghue B, et al. Prioritizing the worries of AML patients: quantifying patient experience using best-worst scaling. Psychooncology. 2021;30:1104\u201311. https:\/\/doi.org\/10.1002\/pon.5652.","journal-title":"Psychooncology"},{"key":"838_CR19","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.2147\/PPA.S421871","volume":"17","author":"L Saini","year":"2023","unstructured":"Saini L, Griffin JD, Pandya BJ, Shah MV, Zhou M, Yang H, et al. Patient and Physician Preferences for Acute Myeloid Leukemia Maintenance Treatments Following Hematopoietic Stem Cell Transplantation. Patient Prefer Adherence. 2023;17:2805\u201319. https:\/\/doi.org\/10.2147\/PPA.S421871.","journal-title":"Patient Prefer Adherence"},{"key":"838_CR20","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1007\/s40273-024-01431-6","volume":"42","author":"J Ride","year":"2024","unstructured":"Ride J, Goranitis I, Meng Y, LaBond C, Lancsar E. A reporting checklist for discrete choice experiments in health: the DIRECT checklist. Pharmacoeconomics. 2024;42:1161\u201375. https:\/\/doi.org\/10.1007\/s40273-024-01431-6.","journal-title":"Pharmacoeconomics"},{"key":"838_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1160966","volume":"13","author":"A Delmas","year":"2023","unstructured":"Delmas A, Batchelder L, Arora I, Bayet S, Bruhn D, Eberhardt A, et al. Exploring preferences of different modes of administration of hypomethylating agent treatments among patients with acute myeloid leukemia. Front Oncol. 2023;13:1160966. https:\/\/doi.org\/10.3389\/fonc.2023.1160966.","journal-title":"Front Oncol"},{"key":"838_CR22","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s40487-016-0029-8","volume":"4","author":"EL Tomaszewski","year":"2016","unstructured":"Tomaszewski EL, Fickley CE, Maddux L, Krupnick R, Bahceci E, Paty J, et al. The patient perspective on living with acute myeloid leukemia. Oncol Ther. 2016;4:225\u201338. https:\/\/doi.org\/10.1007\/s40487-016-0029-8.","journal-title":"Oncol Ther"},{"key":"838_CR23","doi-asserted-by":"publisher","DOI":"10.2196\/14285","volume":"21","author":"A Booth","year":"2019","unstructured":"Booth A, Bell T, Halhol S, Pan S, Welch V, Merinopoulou E, et al. Using social media to uncover treatment experiences and decisions in patients with acute myeloid leukemia or myelodysplastic syndrome who are ineligible for intensive chemotherapy: patient-centric qualitative data analysis. J Med Internet Res. 2019;21:e14285. https:\/\/doi.org\/10.2196\/14285.","journal-title":"J Med Internet Res"},{"key":"838_CR24","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1080\/03007995.2018.1456414","volume":"34","author":"J Seo","year":"2018","unstructured":"Seo J, Smith BD, Estey E, Voyard E, O\u2019 Donoghue B, Bridges JFP. Developing an instrument to assess patient preferences for benefits and risks of treating acute myeloid leukemia to promote patient-focused drug development. Curr Med Res Opin. 2018;34:2031\u20139. https:\/\/doi.org\/10.1080\/03007995.2018.1456414.","journal-title":"Curr Med Res Opin"},{"key":"838_CR25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12955-021-01711-1","volume":"19","author":"X Zeng","year":"2021","unstructured":"Zeng X, Sui M, Liu R, Qian X, Li W, Zheng E, et al. Assessment of the health utility of patients with leukemia in China. Health Qual Life Outcomes. 2021;19:65. https:\/\/doi.org\/10.1186\/s12955-021-01711-1.","journal-title":"Health Qual Life Outcomes"},{"key":"838_CR26","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s11136-020-02644-w","volume":"30","author":"H Yu","year":"2021","unstructured":"Yu H, Zeng X, Sui M, Liu R, Tan RL-Y, Yang J, et al. A head-to-head comparison of measurement properties of the EQ-5D-3L and EQ-5D-5L in acute myeloid leukemia patients. Qual Life Res. 2021;30:855\u201366. https:\/\/doi.org\/10.1007\/s11136-020-02644-w.","journal-title":"Qual Life Res"},{"key":"838_CR27","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.2217\/fon-2018-0842","volume":"15","author":"CM Mamolo","year":"2019","unstructured":"Mamolo CM, Cappelleri JC, Hoang CJ, Kim R, Hadfield A, Middleton C, et al. A real-world, cross-sectional, community survey of symptoms and health-related quality of life of adults with acute myeloid leukemia. Future Oncol. 2019;15:1895\u2013909. https:\/\/doi.org\/10.2217\/fon-2018-0842.","journal-title":"Future Oncol"},{"key":"838_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-025-02419-2","volume":"23","author":"W Wu","year":"2025","unstructured":"Wu W, Wang Y, Wu Y, Wu F, Yang W, Tang F, et al. Health-related quality of life and financial toxicity in Chinese patients with multiple myeloma: a two-year real-world multicentre study. Health Qual Life Outcomes. 2025;23:87. https:\/\/doi.org\/10.1186\/s12955-025-02419-2.","journal-title":"Health Qual Life Outcomes"},{"key":"838_CR29","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s40273-022-01198-8","volume":"41","author":"S Jiang","year":"2023","unstructured":"Jiang S, Ren R, Gu Y, Jeet V, Liu P, Li S. Patient preferences in targeted pharmacotherapy for cancers: a systematic review of discrete choice experiments. Pharmacoeconomics. 2023;41:43\u201357. https:\/\/doi.org\/10.1007\/s40273-022-01198-8.","journal-title":"Pharmacoeconomics"},{"key":"838_CR30","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1038\/s41375-025-02735-y","volume":"39","author":"E Telzerow","year":"2025","unstructured":"Telzerow E, G\u00f6rlich D, Sauerland C, Rothenberg-Thurley M, Moret AS, Krau\u00df SM, et al. Quality of life and life satisfaction in long-term survivors of acute myeloid leukemia. Leukemia. 2025;39:2663\u201372. https:\/\/doi.org\/10.1038\/s41375-025-02735-y.","journal-title":"Leukemia"},{"key":"838_CR31","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40271-024-00672-z","volume":"17","author":"NB Campoamor","year":"2024","unstructured":"Campoamor NB, Guerrini CJ, Brooks WB, Bridges JFP, Crossnohere NL. Pretesting discrete-choice experiments: a guide for researchers. Patient (Auckl). 2024;17:109\u201320. https:\/\/doi.org\/10.1007\/s40271-024-00672-z.","journal-title":"Patient (Auckl)"},{"key":"838_CR32","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1177\/002224379603300305","volume":"33","author":"J Huber","year":"1996","unstructured":"Huber J, Zwerina K. The importance of utility balance in efficient choice designs. J Mark Res. 1996;33:307\u201317. https:\/\/doi.org\/10.1177\/002224379603300305.","journal-title":"J Mark Res"},{"key":"838_CR33","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.jval.2016.07.003","volume":"19","author":"R Norman","year":"2016","unstructured":"Norman R, Kemmler G, Viney R, Pickard AS, Gamper E, Holzner B, et al. Order of presentation of dimensions does not systematically bias utility weights from a discrete choice experiment. Value Health. 2016;19:1033\u20138. https:\/\/doi.org\/10.1016\/j.jval.2016.07.003.","journal-title":"Value Health"},{"key":"838_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocm.2024.100494","volume":"52","author":"MF Jonker","year":"2024","unstructured":"Jonker MF. Level overlap and level color coding revisited: improved attribute attendance and higher choice consistency in discrete choice experiments. J Choice Model. 2024;52:100494. https:\/\/doi.org\/10.1016\/j.jocm.2024.100494.","journal-title":"J Choice Model"},{"key":"838_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0111805","volume":"9","author":"J Veldwijk","year":"2014","unstructured":"Veldwijk J, Lambooij MS, Bekker-Grob EW, Smit HA, Wit GA. The effect of including an opt-out option in discrete choice experiments. PLoS ONE. 2014;9:e111805. https:\/\/doi.org\/10.1371\/journal.pone.0111805.","journal-title":"PLoS ONE"},{"key":"838_CR36","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.jval.2018.04.1822","volume":"21","author":"T Tervonen","year":"2018","unstructured":"Tervonen T, Schmidt-Ott T, Marsh K, Bridges JFP, Quaife M, Janssen E. Assessing rationality in discrete choice experiments in health: an investigation into the use of dominance tests. Value Health. 2018;21:1192\u20137. https:\/\/doi.org\/10.1016\/j.jval.2018.04.1822.","journal-title":"Value Health"},{"key":"838_CR37","unstructured":"Johnson R, Orme B. Getting the Most from CBC. Sequim: Sawtooth Software Research Paper Series, Sawtooth Software; 2003."},{"key":"838_CR38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40271-020-00467-y","volume":"14","author":"A Pearce","year":"2021","unstructured":"Pearce A, Harrison M, Watson V, Street DJ, Howard K, Bansback N, et al. Respondent understanding in discrete choice experiments: a scoping review. Patient. 2021;14:17\u201353. https:\/\/doi.org\/10.1007\/s40271-020-00467-y.","journal-title":"Patient"},{"key":"838_CR39","first-page":"105","volume-title":"Frontiers in econometrics","author":"D McFadden","year":"1974","unstructured":"McFadden D. Conditional logit analysis of qualitative choice behavior. In: Zarembka P, editor. Frontiers in econometrics. New York: Academic Press; 1974. p. 105\u201342."},{"key":"838_CR40","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jval.2016.04.004","volume":"19","author":"AB Hauber","year":"2016","unstructured":"Hauber AB, Gonz\u00e1lez JM, Groothuis-Oudshoorn CGM, Prior T, Marshall DA, Cunningham C, et al. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR Conjoint Analysis Good Research Practices Task Force. Value Health. 2016;19:300\u201315. https:\/\/doi.org\/10.1016\/j.jval.2016.04.004.","journal-title":"Value Health"},{"key":"838_CR41","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jocm.2016.09.005","volume":"21","author":"A Daly","year":"2016","unstructured":"Daly A, Dekker T, Hess S. Dummy coding vs effects coding for categorical variables: clarifications and extensions. J Choice Model. 2016;21:36\u201341. https:\/\/doi.org\/10.1016\/j.jocm.2016.09.005.","journal-title":"J Choice Model"},{"key":"838_CR42","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s40271-019-00360-3","volume":"12","author":"JM Gonzalez","year":"2019","unstructured":"Gonzalez JM. A guide to measuring and interpreting attribute importance. Patient (Auckl). 2019;12:287\u201395. https:\/\/doi.org\/10.1007\/s40271-019-00360-3.","journal-title":"Patient (Auckl)"},{"key":"838_CR43","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13561-025-00658-z","volume":"15","author":"C Ong","year":"2025","unstructured":"Ong C, Cook AR, Tan K-K, Wang Y. Calculating willingness-to-pay with discrete cost and random coefficients in discrete choice experiments. Health Econ Rev. 2025;15:63. https:\/\/doi.org\/10.1186\/s13561-025-00658-z.","journal-title":"Health Econ Rev."},{"key":"838_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.697711","volume":"12","author":"Y Sugitani","year":"2021","unstructured":"Sugitani Y, Ito K, Ono S. Patient preferences for attributes of chemotherapy for lung cancer: discrete choice experiment study in Japan. Front Pharmacol. 2021;12:697711. https:\/\/doi.org\/10.3389\/fphar.2021.697711.","journal-title":"Front Pharmacol"},{"key":"838_CR45","doi-asserted-by":"publisher","first-page":"e808","DOI":"10.1016\/S2352-3026(25)00236-4","volume":"12","author":"W Yin","year":"2025","unstructured":"Yin W, Yan X, Cai J, Han B, Yin P, Lu G, et al. Incidence, mortality, and survival associated with acute leukaemia subtypes by age group in China: a population-based cancer registry analysis and cohort study. Lancet Haematol. 2025;12:e808\u201322. https:\/\/doi.org\/10.1016\/S2352-3026(25)00236-4.","journal-title":"Lancet Haematol."},{"key":"838_CR46","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1377\/hlthaff.2011.1300","volume":"31","author":"DN Lakdawalla","year":"2012","unstructured":"Lakdawalla DN, Romley JA, Sanchez Y, Maclean JR, Penrod JR, Philipson T. How cancer patients value hope and the implications for cost-effectiveness assessments of high-cost cancer therapies. Health Aff. 2012;31:676\u201382. https:\/\/doi.org\/10.1377\/hlthaff.2011.1300.","journal-title":"Health Aff"},{"key":"838_CR47","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/j.jval.2021.04.1284","volume":"24","author":"SD Reed","year":"2021","unstructured":"Reed SD, Yang J-C, Gonzalez JM, Johnson FR. Quantifying value of hope. Value Health. 2021;24:1511\u20139. https:\/\/doi.org\/10.1016\/j.jval.2021.04.1284.","journal-title":"Value Health"},{"key":"838_CR48","doi-asserted-by":"publisher","first-page":"5002","DOI":"10.1007\/s12325-021-01872-x","volume":"38","author":"E Yucel","year":"2021","unstructured":"Yucel E, Zhang S, Panjabi S. Health-related and economic burden among family caregivers of patients with acute myeloid leukemia or hematological malignancies. Adv Ther. 2021;38:5002\u201324. https:\/\/doi.org\/10.1007\/s12325-021-01872-x.","journal-title":"Adv Ther"},{"key":"838_CR49","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1016\/j.jval.2022.05.003","volume":"25","author":"M Zhang","year":"2022","unstructured":"Zhang M, He X, Wu J, Wang X, Jiang Q, Xie F. How do treatment preferences of patients with cancer compare with those of oncologists and family members? Evidence from a discrete choice experiment in China. Value Health. 2022;25:1768\u201377. https:\/\/doi.org\/10.1016\/j.jval.2022.05.003.","journal-title":"Value Health"},{"key":"838_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00668-8","volume":"12","author":"KW Pratz","year":"2022","unstructured":"Pratz KW, Panayiotidis P, Recher C, Wei X, Jonas BA, Montesinos P, et al. Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia. Blood Cancer J. 2022;12:71. https:\/\/doi.org\/10.1038\/s41408-022-00668-8.","journal-title":"Blood Cancer J"},{"key":"838_CR51","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41408-025-01346-1","volume":"15","author":"N Gangat","year":"2025","unstructured":"Gangat N, Dinardo CD. Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithms. Blood Cancer J. 2025;15:139. https:\/\/doi.org\/10.1038\/s41408-025-01346-1.","journal-title":"Blood Cancer J"},{"key":"838_CR52","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkae093","volume":"8","author":"AM Planey","year":"2024","unstructured":"Planey AM, Spees LP, Biddell CB, Waters A, Jones EP, Hecht HK, et al. The intersection of travel burdens and financial hardship in cancer care: a scoping review. JNCI Cancer Spectr. 2024;8:pkae093. https:\/\/doi.org\/10.1093\/jncics\/pkae093.","journal-title":"JNCI Cancer Spectr"},{"key":"838_CR53","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.jval.2024.02.020","volume":"27","author":"SR Hill","year":"2024","unstructured":"Hill SR, Gibson A, Oluboyede Y, Longworth L, Bennett B, Shaw JW. A methodological study to compare alternative modes of administration to value EQ-5D using preference-elicitation techniques. Value Health. 2024;27:784\u201393. https:\/\/doi.org\/10.1016\/j.jval.2024.02.020.","journal-title":"Value Health"}],"container-title":["The Patient - Patient-Centered Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-026-00838-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40271-026-00838-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-026-00838-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:57:18Z","timestamp":1789055838000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40271-026-00838-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":53,"alternative-id":["838"],"URL":"https:\/\/doi.org\/10.1007\/s40271-026-00838-x","relation":{},"ISSN":["1178-1653","1178-1661"],"issn-type":[{"value":"1178-1653","type":"print"},{"value":"1178-1661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"assertion":[{"value":"12 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol of this  study received approval from the Ethics Committee of Harbin Medical University (HMUIRB2023005) and was conducted in accordance with the principles outlined in the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All individuals in the current study provided informed consent.","order":4,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Conceptualization: LW, HL, MT and JH. Data curation: LW, DL, HL and HY. Formal analysis: LW and HL. Funding acquisition: WH. Methodology: LW, HL and MT. Project administration: WH and HY. Supervision: WH and HY. Validation: JH, YW, MT and DL. Visualization: LW and HL. Writing\u2014original draft: LW. Writing\u2014review and editing: LW and HL. All authors read and approved the final manuscript. Weidong Huang is the leading corresponding author.","order":6,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data are available from the corresponding author upon reasonable request.","order":7,"name":"Ethics","label":"Availability of data and code","group":{"name":"EthicsHeading","label":"Declarations"}}]}}